Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 335-339

  Kohl, Steve ^a,c,e   Charlebois, Edwin D ^a   Sigouroudinia, Mavash ^a   Goldbeck, Cheryl ^b   Hartog, Karin ^b   Sekulovich, Rose E ^b   Langenberg, Andria G M ^b   Burke, Rae Lyn ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Biotechnology Solutions   (United States)

^e SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; PRIORITY JOURNAL; SEROCONVERSION;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; VACCINATION; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 0033979991     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315208     Document Type: Article

References (15)

1. 1. Fleming DT, McQuillan GM, Johnson RE, et al.Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-11.
2. 2. Langenberg AGM, Burke RL, Adair SF, et al. A recombinant glycoprotein vaccine for herpes simplex type 2: safety and immunogenicity. Ann Intern Med 1995; 122:889-98.
3. 3. Corey L, Langenberg AGM, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 1999; 282:331-46.
4. 4. Straus SE, Wald A, Kost PG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoprotein D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997; 176: 1129-34.
5. 5. Sanchez-Pescador L, Pereira L, Charleboìs ED, Kohl S. Antibodies to epitopes of herpes simplex virus type 1 glycoprotein B (gB) in human sera: analysis of functional gB epitopes defined by inhibition of murine monoclonal antibodies. J Infect Dis 1993; 168:844-53.
6. 6. Kohl S. Neonatal herpes simplex virus infection. In: Stoll BJ, Weisman L, eds. Infection in perinatology. Clin perinatology 1997; 24:129-50.
7. 7. Schmidt OW, Fife K, Corey L. Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes. J Infect Dis 1984; 149: 645-6.
8. 8. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections, clinical manifestations, course and complications. Ann Intern Med 1983; 98:958-72.
9. 9. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116:197-202.
10. 10. Whitley RJ. Neonatal herpes simplex virus infections: is there a role for immunoglobulin in disease prevention and therapy? Pediatr Infect Dis J 1994; 13:432-9.
11. 11. Kohl S. The role of antibody in herpes simplex virus infection in humans. In: Rouse BT, ed. Herpes simplex virus: pathogenesis, immunobiology and control: current topics in microbiology and immunology. Berlin: Springer-Verlag, 1992;75-88.
12. 12. Kohl S. Role of antibody-dependent cellular cytotoxicity in defense against herpes simplex virus infection. Rev Infect Dis 1991; 13:108-14.
13. 13. Kohl S, Adam E, Matson DO, Kaufman RH, Dreesman GR. Kinetics of human antibody response to primary genital herpes simplex virus infection. Intervirology 1982; 18:164-8.
14. 14. Ashley RL, Crisostomo FM, Doss M, et al. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine. J Infect Dis 1998; 178:1-7.
15. 15. Kohl S, Strynadka NCJ, Hodges RS, Pereira L. Analysis of the role of antibody-dependent cellular cytotoxicity antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B. J Clin Invest 1990; 86:273-8.